209 related articles for article (PubMed ID: 31449350)
1. Ubiquitin C-Terminal Hydrolase L1: Biochemical and Cellular Characterization of a Covalent Cyanopyrrolidine-Based Inhibitor.
Krabill AD; Chen H; Hussain S; Feng C; Abdullah A; Das C; Aryal UK; Post CB; Wendt MK; Galardy PJ; Flaherty DP
Chembiochem; 2020 Mar; 21(5):712-722. PubMed ID: 31449350
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a Potent and Selective Covalent Inhibitor and Activity-Based Probe for the Deubiquitylating Enzyme UCHL1, with Antifibrotic Activity.
Panyain N; Godinat A; Lanyon-Hogg T; Lachiondo-Ortega S; Will EJ; Soudy C; Mondal M; Mason K; Elkhalifa S; Smith LM; Harrigan JA; Tate EW
J Am Chem Soc; 2020 Jul; 142(28):12020-12026. PubMed ID: 32579346
[TBL] [Abstract][Full Text] [Related]
3. Covalent Fragment Screening and Optimization Identifies the Chloroacetohydrazide Scaffold as Inhibitors for Ubiquitin C-terminal Hydrolase L1.
Imhoff RD; Patel R; Safdar MH; Jones HBL; Pinto-Fernandez A; Vendrell I; Chen H; Muli CS; Krabill AD; Kessler BM; Wendt MK; Das C; Flaherty DP
J Med Chem; 2024 Mar; 67(6):4496-4524. PubMed ID: 38488146
[TBL] [Abstract][Full Text] [Related]
4. Optimization and Anti-Cancer Properties of Fluoromethylketones as Covalent Inhibitors for Ubiquitin C-Terminal Hydrolase L1.
Krabill AD; Chen H; Hussain S; Hewitt CS; Imhoff RD; Muli CS; Das C; Galardy PJ; Wendt MK; Flaherty DP
Molecules; 2021 Feb; 26(5):. PubMed ID: 33668938
[TBL] [Abstract][Full Text] [Related]
5. Ubiquitin C-terminal hydrolase-L1 has prognostic relevance and is a therapeutic target for high-grade neuroendocrine lung cancers.
Shimada Y; Kudo Y; Maehara S; Matsubayashi J; Otaki Y; Kajiwara N; Ohira T; Minna JD; Ikeda N
Cancer Sci; 2020 Feb; 111(2):610-620. PubMed ID: 31845438
[TBL] [Abstract][Full Text] [Related]
6. UCHL1 as a novel target in breast cancer: emerging insights from cell and chemical biology.
Mondal M; Conole D; Nautiyal J; Tate EW
Br J Cancer; 2022 Jan; 126(1):24-33. PubMed ID: 34497382
[TBL] [Abstract][Full Text] [Related]
7. Structural basis for specific inhibition of the deubiquitinase UCHL1.
Grethe C; Schmidt M; Kipka GM; O'Dea R; Gallant K; Janning P; Gersch M
Nat Commun; 2022 Oct; 13(1):5950. PubMed ID: 36216817
[TBL] [Abstract][Full Text] [Related]
8. Development of Ubiquitin Variants with Selectivity for Ubiquitin C-Terminal Hydrolase Deubiquitinases.
Hewitt CS; Krabill AD; Das C; Flaherty DP
Biochemistry; 2020 Sep; 59(37):3447-3462. PubMed ID: 32865982
[TBL] [Abstract][Full Text] [Related]
9. Activity-based protein profiling reveals deubiquitinase and aldehyde dehydrogenase targets of a cyanopyrrolidine probe.
Panyain N; Godinat A; Thawani AR; Lachiondo-Ortega S; Mason K; Elkhalifa S; Smith LM; Harrigan JA; Tate EW
RSC Med Chem; 2021 Nov; 12(11):1935-1943. PubMed ID: 34820624
[TBL] [Abstract][Full Text] [Related]
10. Small-Molecule Activity-Based Probe for Monitoring Ubiquitin C-Terminal Hydrolase L1 (UCHL1) Activity in Live Cells and Zebrafish Embryos.
Kooij R; Liu S; Sapmaz A; Xin BT; Janssen GMC; van Veelen PA; Ovaa H; Dijke PT; Geurink PP
J Am Chem Soc; 2020 Sep; 142(39):16825-16841. PubMed ID: 32886496
[TBL] [Abstract][Full Text] [Related]
11. Ubiquitin C-terminal hydrolase L1 is required for pancreatic beta cell survival and function in lipotoxic conditions.
Chu KY; Li H; Wada K; Johnson JD
Diabetologia; 2012 Jan; 55(1):128-40. PubMed ID: 22038515
[TBL] [Abstract][Full Text] [Related]
12. Ubiquitin C-terminal hydrolase 1: A novel functional marker for liver myofibroblasts and a therapeutic target in chronic liver disease.
Wilson CL; Murphy LB; Leslie J; Kendrick S; French J; Fox CR; Sheerin NS; Fisher A; Robinson JH; Tiniakos DG; Gray DA; Oakley F; Mann DA
J Hepatol; 2015 Dec; 63(6):1421-8. PubMed ID: 26264933
[TBL] [Abstract][Full Text] [Related]
13. Ubiquitin C-Terminal Hydrolase L1 regulates autophagy by inhibiting autophagosome formation through its deubiquitinating enzyme activity.
Yan C; Huo H; Yang C; Zhang T; Chu Y; Liu Y
Biochem Biophys Res Commun; 2018 Mar; 497(2):726-733. PubMed ID: 29462615
[TBL] [Abstract][Full Text] [Related]
14. High Expression of Ubiquitin C-terminal Hydrolase L1 Is Associated With Poor Prognosis in Endometrial Cancer Patients.
Nakao K; Hirakawa T; Suwa H; Kogure K; Ikeda S; Yamashita S; Minegishi T; Kishi H
Int J Gynecol Cancer; 2018 May; 28(4):675-683. PubMed ID: 29489474
[TBL] [Abstract][Full Text] [Related]
15. Ubiquitin carboxy-terminal hydrolase L1 - physiology and pathology.
Matuszczak E; Tylicka M; Komarowska MD; Debek W; Hermanowicz A
Cell Biochem Funct; 2020 Jul; 38(5):533-540. PubMed ID: 32207552
[TBL] [Abstract][Full Text] [Related]
16. Ubiquitin C-terminal hydrolase isozyme L1 is associated with shelterin complex at interstitial telomeric sites.
Ilic A; Lu S; Bhatia V; Begum F; Klonisch T; Agarwal P; Xu W; Davie JR
Epigenetics Chromatin; 2017 Nov; 10(1):54. PubMed ID: 29126443
[TBL] [Abstract][Full Text] [Related]
17. Ubiquitin carboxyl-terminal esterase L1 (UCHL1) is associated with stem-like cancer cell functions in pediatric high-grade glioma.
Sanchez-Diaz PC; Chang JC; Moses ES; Dao T; Chen Y; Hung JY
PLoS One; 2017; 12(5):e0176879. PubMed ID: 28472177
[TBL] [Abstract][Full Text] [Related]
18. The co-crystal structure of ubiquitin carboxy-terminal hydrolase L1 (UCHL1) with a tripeptide fluoromethyl ketone (Z-VAE(OMe)-FMK).
Davies CW; Chaney J; Korbel G; Ringe D; Petsko GA; Ploegh H; Das C
Bioorg Med Chem Lett; 2012 Jun; 22(12):3900-4. PubMed ID: 22617491
[TBL] [Abstract][Full Text] [Related]
19. Ubiquitin C-terminal hydrolase L1 promotes expression of programmed cell death-ligand 1 in non-small-cell lung cancer cells.
Mao R; Tan X; Xiao Y; Wang X; Wei Z; Wang J; Wang X; Zhou H; Zhang L; Shi Y
Cancer Sci; 2020 Sep; 111(9):3174-3183. PubMed ID: 32539182
[TBL] [Abstract][Full Text] [Related]
20. Control of BACE1 degradation and APP processing by ubiquitin carboxyl-terminal hydrolase L1.
Zhang M; Deng Y; Luo Y; Zhang S; Zou H; Cai F; Wada K; Song W
J Neurochem; 2012 Mar; 120(6):1129-38. PubMed ID: 22212137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
